Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 2, 1996, Pages 139-146

  Sato, Naohide ^a   Gleave, Martin E ^a,c   Bruchovsky, Nicholas ^a   Rennie, Paul S ^a   Goldenberg, S Larry ^a   Lange, Paul H ^b   Sullivan, Lorne D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE PROPIONATE;

ANIMAL MODEL; ARTICLE; CASTRATION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG WITHDRAWAL; GENE CONTROL; MOUSE; NONHUMAN; PROSTATE CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH;

ANIMALIA;

EID: 0030152008     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00018-0     Document Type: Article

References (32)

1. 1. Huggins C. and Hodges C. V.: Studies on prostate cancer. I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1 (1941) 293-297.
2. 2. Crawford E. D., Eisenberger M. A., McLeod D. G., Spaulding J. T., Benson R., Dorr F. A., Blumenstein B. A., Davis M. A. and Goodman P. J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med. 313 (1989) 419-424.
3. 3. Béland G.: Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study. Urology 37, Suppl 2 (1991) 25-29.
4. 4. Denis L. J., Carnelro de Moura J. L., Bono A., Sylvester R., Whelan P., Newling D. and Depauw M.: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial. Urology 42 (1993) 119-129.
5. 5. Janknegt R. A., Abbou C. C., Bartoletti R., Bernstein-Hahn L., Bracken B., Brisse J. M., Da Silva F. C., Chisholm G., Crawford E. D. and Debruyne F. M.: Orchiectomy and Anandron (Nilutamide) or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J. Urol. 149 (1993) 77-83.
6. 6. Miller J. I., Ahmann F. R., Drach G. W., Emerson S. S. and Bottaccini M. R.: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J. Urol. 147 (1992) 956-961.
7. 7. Hsieh J.-T., Wu H.-C., Gleave M. E., von Eschenbach A. C. and Chung L. W. K.: Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res. 53 (1993) 2852-2857.
8. 8. Gleave M., Hsieh J.-T., Gao C., von Eschenbach A. C. and Chung L. W. K.: Acceleration of human prostate cancer in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 51 (1991) 3753-3761.
9. 9. Gleave M. E., Hsieh J.-T., von Eschenbach A. C. and Chung L. W. K.: Prostate and bone fibroblasts induce human prostate cancer growth in vivo; implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J. Urol. 147 (1992) 1151-1159.
10. 10. Gleave M., Hsieh J.-T., Wu H.-C., von Eschenbach A. C. and Chung L. W. K.: Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res. 52 (1992) 1598-1605.
11. 11. Bruchovsky N., Rennie P. S., Coldman A. J., Goldenberg S. L., To M. and Lawson D.: Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 50 (1990) 2275-2282.
12. 12. Akakura K., Bruchovsky N., Goldenberg S. L., Rennie P. S., Buckley A. R. and Sullivan L. D.: Effects of intermittent androgen suppression on androgen-dependent tumors; apoptosis and serum prostate-specific antigen. Cancer 71 (1993) 2782-2790.
13. 13. Janek P., Briand P. and Hartman N. R.: The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 35 (1975) 3698-3704.
14. 14. Chomczynski P. and Sacchi N.: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Analyt. Biochem. 162 (1987) 156-159.
15. 15. Lundwall Å. and Lilja H.: Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 214 (1987) 317-322.
16. 16. Wu, C.-P. and Gu, F.-L.: The prostate in eunuchs. In EORTC Genitourinary Group Monograph 10 - Urologic Oncology; Reconstructive Surgery, Organ Preservation, and Restoration of Function. Wiley-Liss Inc., New York (1992) pp. 249-255.
17. 17. Isaacs J. T. and Coffey D. S.: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 41 (1981) 5070-5075.
18. 18. van Weerden, W. M.: Animal models in the study of progression of prostate and breast cancers to endocrine independency. In Mechanisms of Progression to Hormone-Independent Growth of Breast and Prostate Cancer (Edited by P. M. J. J. Berns, J. C. Romijin and F. H. Schröder). Parthenon Publishers, New Jersey (1991) pp. 55-70.
19. 19. Isaacs J. T., Wake N., Coffey D. S. and Sandberg A. A.: Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer. Cancer Res. 42 (1982) 2353-2361.
20. 20. Russo P., Liguori G., Heston W. D. W., Huryk R., Yang C.-R., Fair W. R., Whitemore W. F. and Herr H. W.: Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma. Cancer Res. 47 (1987) 5967-5970.
21. 21. Issacs J. T.: The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 5 (1984) 1-17.
22. 22. Rennie P. S., Bruchovsky N., Buttyan R., Benson M. and Cheng H.: Gene expression during the early phases of regression of the androgen-dependent Shionogi mouse mammary carcinoma. Cancer Res. 48 (1988) 6309-6312.
23. 23. Gleave M. E., Hsieh J.-T., Wu H.-C., von Eschenbach A. C. and Chung L. W. K.: Evaluation of the pharmacokinetics of PSA using the LNCaP tumor model. J. Urol. 147 (1992) 386A.
24. 24. Wu H.-C., Hsieh J. T., Gleave M. E., Brown N. M., Pathak S. and Chung L. W. K.: Derivation of androgen-independent human LNCaP prostate cancer sublines: role of bone stromal cells. Int. J. Cancer 57 (1994) 406-412.
25. 25. Hsieh J.-T., Gleave M. E., Wu H.-C., Wang X.-H. and Chung L. W. K. : Deranged control of androgen-regulated gene in the relapse stage of human prostatic cancer after castration; Implication for the derivation of androgen-independent cells by adaptive mechanisms. J. Urol. 147 (1992) 414A.
26. 26. Gleave M. E., Bowden M., Goldenberg S. L., Bruchovsky N. and Sullivan L. D.: Predictors of androgen independent PSA progression in the LNCaP model. J. Urol. 151 (1994) 248A.
27. 27. Kokontis J., Takakura K., Hay N. and Liao S.: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54 (1994) 1566-1573.
28. 28. Farber E.: Clonal adaptation during carcinogenesis. Biochem. Pharmacol. 39 (1990) 1837-1846.
29. 29. Noble R. L.: The development of prostatic adenocarcinoma in the Nb rat following prolonged sex hormone administration. Cancer Res. 37 (1977) 1929-1933.
30. 30. Oesterling J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145 (1991) 907-923.
31. 31. Klotz L. H., Kerr H. W., Morse M. J. and Whitmore W. F., Jr.: Intermittent endocrine therapy for advanced prostate cancer. Cancer 58 (1986) 2546-2550.
32. 32. Goldenberg S. L., Bruchovsky N., Gleave M. E., Sullivan L. D. and Akakura K.: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45 (1995) 839-845.